Alnylam Pharmaceuticals Inc (ALNY):製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】Alnylam Pharmaceuticals Inc (ALNY) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C10081)・商品コード:DATA904C10081
・発行会社(調査会社):GlobalData
・発行日:2018年11月
・ページ数:142
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥27,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥54,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥81,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000を加算
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
Alnylam Pharmaceuticals Inc (Alnylam) is a biopharmaceutical company which discovers, develops and commercializes therapeutics based on Ribo Nucleic Acid interference (RNAi). The company offers a broad pipeline of investigational RNAi therapeutics in the areas of genetic medicines, hepatic infectious diseases, cardio-metabolic diseases, and central nervous system (CNS) diseases. Its late stage product candidates include Patisiran for hereditary transthyretin-mediated (hATTR) amyloidosis, Inclisiran for hypercholesterolemia, Fitusiran for hemophilia and rare bleeding disorders and Givosiran for acute hepatic porphyrias. It operates subsidiaries in the US, Canada, France, Germany, Italy, Spain, Sweden, the Netherlands, Switzerland and the UK. Alnylam is headquartered in Cambridge, Massachusetts, the US.

Alnylam Pharmaceuticals Inc (ALNY) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 6
Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Alnylam Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 11
Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 14
Partnerships 14
Alnylam Pharma and Sanofi Enter into Agreement 14
Regeneron Pharma Enters into Agreement with Alnylam Pharma 15
Invitae Enters into Agreement with Alnylam Pharma 16
Alnylam Pharma Enters into Agreement with Sanofi Genzyme 17
BioXcel Enters into Agreement with Alnylam Pharma 18
Alnylam Pharma And Genzyme Enter Into Agreement For RNAi Therapeutics As Genetic Medicines 19
Alnylam Pharma And Genzyme Expands Co-Development Agreement For RNAi Therapeutics 21
Licensing Agreements 22
Vir Biotechnology Enters into Licensing Agreement with Alnylam Pharma 22
Medicines Company Enters Into Licensing Agreement With Alnylam Pharma To Develop And Commercialize RNAi Therapeutics Targeting PCSK9 23
Tekmira Pharma Enters Into Licensing Agreement With Alnylam Pharma 25
Alnylam Pharma Enters Into Licensing Agreement With Arrowhead Research 26
Arrowhead Research Enters Into Licensing Agreement With Alnylam Pharma 27
Alnylam Pharma Enters Into Licensing Agreement With Ascletis Pharma (Hangzhou) To Develop ALN-VSP 28
Alnylam Pharma Enters Into Licensing Agreement With Plant Bioscience For Baulcombe Patent 29
Equity Offering 30
Alnylam Pharma Raises USD805 Million in Public Offering of Shares 30
Alnylam Pharma Raises USD359.4 Million in Public Offering of Shares 32
Alnylam Pharma Raises USD518 Million in Public Offering of Shares 34
Alnylam Pharma Raises USD70.7 Million in Private Placement of Shares 36
Alnylam Pharma Completes Public Offering Of Shares For US$185 Million 37
Alnylam Pharma Completes Private Placement Of Shares For US$185 Million 39
Alnylam Pharma Completes Public Offering Of Shares For US$93 Million 41
Acquisition 43
Alnylam Pharma Acquires Sirna Therapeutics From Merck 43
Alnylam Pharmaceuticals Inc – Key Competitors 44
Alnylam Pharmaceuticals Inc – Key Employees 45
Alnylam Pharmaceuticals Inc – Locations And Subsidiaries 46
Head Office 46
Other Locations & Subsidiaries 46
Joint Venture 47
Recent Developments 48
Strategy And Business Planning 48
Jan 07, 2018: Alnylam Announces 2018 Corporate Goals 48
Financial Announcements 50
Nov 07, 2018: Alnylam Pharmaceuticals reports third quarter 2018 financial results and highlights recent period activity 50
Aug 02, 2018: Alnylam Pharmaceuticals reports second quarter 2018 financial results and highlights recent period activity 53
May 03, 2018: Alnylam Pharmaceuticals Reports First Quarter 2018 Financial Results and Highlights Recent Period Activity 57
Feb 08, 2018: Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Period Activity 60
Aug 09, 2017: Alnylam Pharmaceuticals Reports Second Quarter 2017 Financial Results and Highlights Recent Period Activity 63
May 05, 2017: Alnylam Pharmaceuticals Reports First Quarter 2017 Financial Results and Highlights Recent Period Activity 65
Feb 08, 2017: Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Highlights Recent Period Activity 67
Corporate Communications 70
Oct 10, 2018: Alnylam appoints Dr. Margaret Hamburg to Board of Directors 70
Jun 20, 2018: Alnylam Pharmaceuticals Announces Senior Management Changes 71
May 15, 2018: Alnylam Appoints Colleen Reitan to the Board of Directors 72
Jun 19, 2017: Alnylam CEO, John Maraganore, Named BIO Chair for 2017-2018 Term 73
May 09, 2017: Alnylam Expands Leadership Team with Multiple Experienced Biotech Leaders 74
Jan 03, 2017: Alnylam Announces Management Change and Key Promotion 76
Legal and Regulatory 77
Oct 03, 2018: Kessler Topaz Meltzer & Check: securities fraud class action filed Against Alnylam Pharmaceuticals 77
Apr 20, 2018: Dicerna Pharmaceuticals Announces Settlement of All Litigation with Alnylam 78
Apr 20, 2018: Alnylam Reaches Settlement Agreement with Dicerna Pharmaceuticals Resolving Trade Secret Misappropriation and Other Pending Litigation 79
Nov 03, 2017: Silence Therapeutics: Update on litigation matters 80
Jul 03, 2017: Silence Therapeutics: Issue of claim in the UK High Courts 81
Government and Public Interest 82
Oct 29, 2018: Hochschulmedizin Zurich and Alnylam host Innovative Medicine lecture on the discovery and clinical applications of RNA interference (RNAi) 82
Oct 24, 2018: Alnylam announces Advocacy for Impact Grants to inspire unique solutions that address unmet needs affecting the rare disease community 83
Mar 21, 2018: Regeneron Genetics Center Publication in New England Journal of Medicine Identifies New Genetic Variant Providing Protection from Chronic Liver Disease 84
Product News 86
11/13/2017: European Medicines Agency (EMA) Grants Alnylam Accelerated Assessment of Patisiran for Patients with Hereditary ATTR (hATTR) Amyloidosis 86
11/03/2017: Alnylam Reports Positive Preliminary Results from Ongoing Phase 1/2 Study of Lumasiran (ALN-GO1) in Patients with Primary Hyperoxaluria Type 1 87
10/03/2018: Kaskela Law LLC Announces Investor Class Action Lawsuit Against Alnylam Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm 89
10/02/2018: Alnylam launches ONPATTRO (patisiran), the first-ever RNAi therapeutic, in Germany 90
09/24/2018: Alnylam Pharmaceuticals receives Priority Review in Canada for Patisiran, an investigational RNAi Therapeutic for the treatment of Hereditary Transthyretin-mediated Amyloidosis (hATTR amyloidosis) with Polyneuropathy 91
08/30/2018: Alnylam receives approval of ONPATTRO (patisiran) in Europe 92
08/20/2018: Veristat congratulates Alnylam on the FDA approval of ONPATTRO (patisiran) 94
08/14/2018: Onpattro is the first FDA-approved treatment for polyneuropathy 95
08/10/2018: Alnylam announces alignment on value-based agreements with leading health insurers and launches comprehensive patient support services for ONPATTRO (patisiran) 96
08/10/2018: Alnylam announces first-ever FDA approval of an RNAi therapeutic, ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults 98
08/03/2018: Alnylam Announces that the United Kingdom’s MHRA Grants Early Access to Patisiran 100
07/27/2018: Alnylam receives positive CHMP opinion for ONPATTRO (patisiran) for the treatment of hereditary transthyretin-mediated amyloidosis in adults with stage 1 or stage 2 polyneuropathy 101
06/08/2018: Alnylam Reports Updated Positive Results from Phase 1/2 Study of Lumasiran in Patients with Primary Hyperoxaluria Type 1 (PH1) 103
03/12/2018: Alnylam Receives Breakthrough Therapy Designation from FDA for Lumasiran 105
Product Approvals 106
Aug 07, 2018: Silence Therapeutics litigation: patisiran EU marketing authorisation imminent 106
Mar 26, 2018: Alnylam Receives European Medicines Agency PRIME Designation for Accelerated Assessment of Lumasiran, an Investigational RNAi Therapeutic for the Treatment of Primary Hyperoxaluria Type 1 (PH1) 107
Feb 01, 2018: Alnylam Announces FDA Acceptance of New Drug Application (NDA) and Priority Review Status for Patisiran, an Investigational RNAi Therapeutic for the Treatment of Hereditary ATTR (hATTR) Amyloidosis 108
Jan 25, 2018: Alnylam Announces EMA Acceptance of Marketing Authorisation Application (MAA) for Patisiran for the Treatment of Hereditary ATTR (hATTR) Amyloidosis 109
Dec 18, 2017: Sanofi and Alnylam Submit Marketing Authorization Application to the EMA for Patisiran for the Treatment of Hereditary ATTR Amyloidosis 110
Dec 12, 2017: Alnylam Completes Submission of New Drug Application to U.S. Food and Drug Administration (FDA) for Patisiran for the Treatment of Hereditary ATTR (hATTR) Amyloidosis 111
Dec 11, 2017: Alnylam Announces Expansion of U.S. Orphan Drug Designation for Patisiran to Treatment of Transthyretin-Mediated Amyloidosis 112
Nov 16, 2017: Alnylam Initiates Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Patisiran for the Treatment of Hereditary ATTR Amyloidosis 113
Clinical Trials 114
Oct 08, 2018: Alnylam reports new positive Phase l/ll results from lumasiran trial 114
Sep 14, 2018: Alnylam announces publication in circulation of exploratory cardiac endpoint data from APOLLO phase 3 study of Patisiran 115
Jul 23, 2018: Alnylam presents new analyses of clinical results from APOLLO phase 3 study of Patisiran at 2018 Peripheral Nerve Society Annual Meeting 117
Jul 04, 2018: Alnylam Announces Publication of APOLLO Phase 3 Clinical Study Results for Investigational RNAi Therapeutic Patisiran in The New England Journal of Medicine 119
Jun 15, 2018: Alnylam to Report New Clinical Results for Patisiran at the 4th Congress of the European Academy of Neurology 121
May 08, 2018: Alnylam Reports Preclinical Data Demonstrating Central Nervous System Delivery of RNAi Therapeutics 123
May 03, 2018: Alnylam Achieves Alignment with FDA on Accelerated Development Path for Lumasiran, an Investigational RNAi Therapeutic for the Treatment of Primary Hyperoxaluria Type 1 (PH1) 124
Apr 24, 2018: Alnylam Reports New Clinical Results from the APOLLO Phase 3 Study of Patisiran at the American Academy of Neurology 2018 Annual Meeting 125
Mar 28, 2018: Alnylam Presents New Clinical Results from the APOLLO Phase 3 Study of Patisiran at the 16th International Symposium on Amyloidosis 127
Mar 14, 2018: Alnylam to Present Clinical Trial Data on Amyloidosis Drug Candidate ALN-TTRsc02 at the 16th International Symposium on Amyloidosis 129
Nov 20, 2017: U.S. Food and Drug Administration (FDA) Grants Alnylam Breakthrough Therapy Designation (BTD) for Patisiran for the Treatment of Hereditary ATTR (hATTR) Amyloidosis with Polyneuropathy 130
Nov 02, 2017: Sanofi and Alnylam Present Positive Complete Results from APOLLO Phase 3 study of Investigational Patisiran in Hereditary ATTR (hATTR) Amyloidosis Patients with Polyneuropathy 132
Oct 20, 2017: Alnylam and Collaborators to Present APOLLO Phase 3 Study Results at 1st European ATTR Amyloidosis Meeting for Patients and Doctors 135
Sep 26, 2017: Alnylam Initiates Phase 2 Clinical Study of Cemdisiran (ALN-CC5) in Patients with Atypical Hemolytic-Uremic Syndrome (aHUS) 136
Sep 20, 2017: Arbutus’ LNP Licensee Alnylam Announces Positive Phase 3 Results for LNP-Enabled Patisiran Program 137
Sep 20, 2017: Sanofi and Alnylam Report Positive Topline Results from APOLLO Phase 3 Study of Patisiran in Hereditary ATTR (hATTR) Amyloidosis Patients with Polyneuropathy 138
Apr 26, 2017: Alnylam Reports Final 24-Month Results from Phase 2 Open-Label Extension Study of Patisiran, an Investigational RNAi Therapeutic in Development for the Treatment of Hereditary ATTR (hATTR) Amyloidosis 140
Appendix 142
Methodology 142
About GlobalData 142
Contact Us 142
Disclaimer 142

List of Tables
Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Alnylam Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 10
Alnylam Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 11
Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Alnylam Pharma and Sanofi Enter into Agreement 14
Regeneron Pharma Enters into Agreement with Alnylam Pharma 15
Invitae Enters into Agreement with Alnylam Pharma 16
Alnylam Pharma Enters into Agreement with Sanofi Genzyme 17
BioXcel Enters into Agreement with Alnylam Pharma 18
Alnylam Pharma And Genzyme Enter Into Agreement For RNAi Therapeutics As Genetic Medicines 19
Alnylam Pharma And Genzyme Expands Co-Development Agreement For RNAi Therapeutics 21
Vir Biotechnology Enters into Licensing Agreement with Alnylam Pharma 22
Medicines Company Enters Into Licensing Agreement With Alnylam Pharma To Develop And Commercialize RNAi Therapeutics Targeting PCSK9 23
Tekmira Pharma Enters Into Licensing Agreement With Alnylam Pharma 25
Alnylam Pharma Enters Into Licensing Agreement With Arrowhead Research 26
Arrowhead Research Enters Into Licensing Agreement With Alnylam Pharma 27
Alnylam Pharma Enters Into Licensing Agreement With Ascletis Pharma (Hangzhou) To Develop ALN-VSP 28
Alnylam Pharma Enters Into Licensing Agreement With Plant Bioscience For Baulcombe Patent 29
Alnylam Pharma Raises USD805 Million in Public Offering of Shares 30
Alnylam Pharma Raises USD359.4 Million in Public Offering of Shares 32
Alnylam Pharma Raises USD518 Million in Public Offering of Shares 34
Alnylam Pharma Raises USD70.7 Million in Private Placement of Shares 36
Alnylam Pharma Completes Public Offering Of Shares For US$185 Million 37
Alnylam Pharma Completes Private Placement Of Shares For US$185 Million 39
Alnylam Pharma Completes Public Offering Of Shares For US$93 Million 41
Alnylam Pharma Acquires Sirna Therapeutics From Merck 43
Alnylam Pharmaceuticals Inc, Key Competitors 44
Alnylam Pharmaceuticals Inc, Key Employees 45
Alnylam Pharmaceuticals Inc, Subsidiaries 46
Alnylam Pharmaceuticals Inc, Joint Venture 47

List of Figures
Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Alnylam Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 11

★調査レポート[Alnylam Pharmaceuticals Inc (ALNY):製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C10081)販売に関する免責事項を必ずご確認ください。
★調査レポート[Alnylam Pharmaceuticals Inc (ALNY):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆